The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease

Lay Summary Biosimilar medications have the potential to significantly reduce the cost of treatment in patients with inflammatory bowel disease. Observational studies have shown similar efficacy and safety of biosimilars to biologic reference products. Shared decision-making is crucial to the successful implementation of these agents.

Automated summary

Biosimilar medications can significantly reduce treatment costs for patients with inflammatory bowel disease. Observational studies have demonstrated similar efficacy and safety between biosimilars and biologic reference products. Shared decision-making is crucial for the successful implementation of these agents.